November 15, 2018
The new and improved iCELLis 500+ bioreactor system will simplify large scale cGMP production of virus for vaccines or gene therapy. New features provide enhanced robust control, reliability, and sustainability of high-density adherent cell growth in an automated format.
Boasting a new stainless steel frame and temperature control unit (TCU), the iCELLis 500+ bioreactor is fully compatible with 21 CFR Part 11 standards and cleanroom requirements.
It features an integrated recipe manager, improved tubing management, and a new temperature control unit (TCU), enabling greater process control, faster filling and draining, and further automations of customer processes for cell and gene therapy and vaccines.
The new and improved iCELLis 500+ bioreactor brings enhanced robust control and reliability to customer processes for viral vector manufacturing of cell and gene therapies, and viruses for vaccines.